Home Cart Sign in  
Chemical Structure| 144689-93-0 Chemical Structure| 144689-93-0

Structure of 144689-93-0

Chemical Structure| 144689-93-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 144689-93-0 ]

CAS No. :144689-93-0
Formula : C12H20N2O3
M.W : 240.30
SMILES Code : OC(C)(C)C1=C([NH]C(=N1)CCC)C(=O)OCC
MDL No. :MFCD07787565
InChI Key :KZBJJAFGNMRRHN-UHFFFAOYSA-N
Pubchem ID :10562026

Safety of [ 144689-93-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of [ 144689-93-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 144689-93-0 ]
  • Downstream synthetic route of [ 144689-93-0 ]

[ 144689-93-0 ] Synthesis Path-Upstream   1~3

  • 1
  • [ 80715-22-6 ]
  • [ 144689-93-0 ]
  • [ 144690-92-6 ]
YieldReaction ConditionsOperation in experiment
98.5%
Stage #1: With tert-butylamine hydrobromide; potassium carbonate In acetone at 0 - 55℃; for 32 h;
Stage #2: With potassium carbonate; potassium iodide In acetone at 20 - 55℃; for 3 h;
Ethyl-4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (100 gm) was dissolved in acetone (2500 ml) and then added potassium carbonate (100 gm), 5-[4'-(bromomethyl)[1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)-1H-tetrazole (250 gm) and tert-butyl ammonium bromide (15 gm) under stirring at room temperature. The temperature of the reaction mass was raised to 50 to 55° C. and maintained for 15 hours at 50 to 55° C. The reaction mass was cooled to 45° C. and passed over celite bed. The collected filtrate was cooled to 0 to 5° C. and then added a solution of potassium carbonate (36 gm) in water (36 ml) for 1 hour. The temperature of the reaction mass was raised to room temperature and maintained for 16 hours at room temperature. The acetone was distilled off completely under vacuum at below 40° C. to obtain residue.
To the residue was added sodium chloride solution (10percent, 900 ml) and then added ethyl acetate (1500 ml).
The layers were separated and the aqueous layer was extracted.
Combined the both organic layers and dried over sodium sulfate.
The solvent was distilled off completely to obtain a residual mass. A mixture of acetone (1200 ml), potassium carbonate (100 gm), (4-bromoethyl)-5-methyl-oxo-1,3-dioxane (105 gm) and potassium iodide (17 gm) were added under stirring at room temperature and then the contents were heated to 50 to 55° C.
The solution was added to the above residual mass for 1 hour 30 minutes and maintained for 1 hour 30 minutes at 50 to 55° C.
The reaction mass was cooled to 45° C. and filtered.
The solvent was distilled off completely to obtain residue.
Toluene (1500 ml) was added to the residue and the layers were separated.
The toluene layer was dried over sodium sulfate and distilled off the layer under vacuum up to obtain clear residual mass.
To the residual mass was added methanol (1500 ml) and stirred for 30 minutes at room temperature.
The reaction mass was cooled to 10 to 15° C. and maintained for 1 hour 30 minutes.
The separated solid was filtered and dried at 40 to 45° C. for 7 hours to obtain 270 gm of trityl olmesartan medoxomil.
Trityl olmesartan medoxomil:
98.5percent;
Trityl olmesartan ethyl ester impurity: 0.35percent;
Bromo trityl olmesartan medoxomil impurity: 0.35percent;
Methyl trityl olmesartan medoxomil impurity: 0.34percent.
References: [1] Patent: US2013/190506, 2013, A1, . Location in patent: Paragraph 0050.
  • 2
  • [ 144689-93-0 ]
  • [ 144690-92-6 ]
References: [1] Patent: WO2011/14611, 2011, A2, .
[2] Patent: WO2012/1694, 2012, A1, .
[3] Patent: WO2012/55994, 2012, A1, .
[4] Patent: CN105481842, 2016, A, .
[5] Patent: KR101526249, 2015, B1, .
[6] Patent: KR101526249, 2015, B1, .
[7] Patent: CN107311989, 2017, A, .
[8] Patent: CN103012382, 2016, B, .
[9] Patent: CN108341804, 2018, A, .
  • 3
  • [ 80841-78-7 ]
  • [ 124750-51-2 ]
  • [ 144689-93-0 ]
  • [ 144690-92-6 ]
References: [1] Patent: WO2011/14611, 2011, A2, . Location in patent: Page/Page column 12; 13.
 

Historical Records

Technical Information

Categories